<DOC>
	<DOCNO>NCT01800695</DOCNO>
	<brief_summary>This study evaluate safety pharmacokinetics ABT-414 subject glioblastoma multiforme .</brief_summary>
	<brief_title>Evaluating Safety Pharmacokinetics ABT-414 Subjects With Glioblastoma Multiforme</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Glioblastoma Multiforme ( GBM ) 2 . 70 Karnofsky Performance Status 3 . Adequate bone marrow function 4 . Recurrent GBM per RANO criterion 5 . Subjects must confirm EGFR amplification central lab 1 . For Subjects recurrent GBM Arm B , subject receive prior treatment bevacizumab , nitrosourea , secondary GBM 2 . For Subjects recurrent GBM Arm C , subject receive prior treatment bevacizumab , secondary GBM 3 . Allergies temozolomide , dacarbazine , IgG contain agent 4 . Anticancer treatment 28 day prior study Day 1 , except Arm B expand cohort temozolomide therapy allow 5 . Subjects one disease recurrence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GBM</keyword>
</DOC>